This page has not been fully approved by the PsychonautWiki administrators.
It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.
|Common names||DBT, N,N-DBT|
|Routes of Administration|
N,N-Dibutyltryptamine, (also known as DBT) is a obscure novel psychedelic substance of the tryptamine class. DBT is strucally related to DMT, along with other analogs such as DiPT, MPT, and MET.
DBT was investigated by Alexander Shulgin and described in his book TiHKAL ("Tryptamines I Have Known and Loved"). Here, he lists a dosage of 1mg/kg intramuscular, though this has been contested by other reports, saying the dosage is larger. It is less active than other similar compounds such as DMT or DET. Aside from this, very little is known about the dosage, effects, and safety profile of the compound.
It is highly advised to use harm reduction practices if using this substance.
DBT, or N,N-dibutyltryptamine, is a member of a family of organic compounds known as tryptamines. Tryptamines share a core structure consisting of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. DBT contains two butyl groups (CH3−CH2−CH2−CH2−) bound to the terminal amine RN at the end of this chain. It contains no ring substitutions, making it a base tryptamine. As with the base compound, any ring substitutions of DBT have very little known of them.
Little is known about the pharmacology of DBT. It has been shown to produce a head-twitch response in mice, meaning it is possibly psychoactive. Some have speculated that it is active orally, possibly due to the long butyl chain, as opposed to a compound such as DMT, which has a much shorter chain and is not active orally on its own.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
No subjective effects of DBT have been reported in the literature, with many reports even suggesting it is only minimally psychoactive.
There are currently 0 experience reports which describe the effects of this substance in our experience index.
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Very little is known about the safety profile of DBT. Because of this, it is strongly recommended that one use harm reduction practices when using this substance.
A lethal dosage of DBT has not been established, partly due to the fact that no attempts to do so have been made.
Tolerance and addiction potential
In studies on rats, minimal rewarding and reinforcing effects were found regarding DBT, as the rats did not reliably self-administer the compound. This is also the case with many other tryptamines.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of DBT. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
DBT is not stated as illegal in any location, but it would possibly fall under analog laws due to its similarity to controlled substances.
- ↑ Shulgin, Alexander; Shulgin, Ann (1997). "#2 DBT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
- ↑ Szara, Stephen. "DMT (N,N-DIMETHYLTRYPTAMINE) AND HOMOLOGUES: CLINICAL AND PHARMACOLOGICAL CONSIDERATIONS".
- ↑ https://en.wikipedia.org/wiki/Dibutyltryptamine. Text "title-Dibutyltryptamine" ignored (help); Missing or empty
- ↑ Abiero A, Ryu IS, Botanas CJ, Custodio RJ, Sayson LV, Kim M, et al. (June 2019). "Four Novel Synthetic Tryptamine Analogs Induce Head-Twitch Responses and Increase 5-HTR2a in the Prefrontal Cortex in Mice". Biomolecules & Therapeutics. 28: 83–91. doi:10.4062/biomolther.2019.049. PMC 6939696 . PMID 31230432.
- ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.